Objectives: To determine whether clomiphene citrate (CC) can be implicated as a cause for central retinal vein occlusion (CRVO) and other visual disturbances. Methods: For this systematic review, we performed a search of the following databases: PubMed (1976 to November 2009), Medline Plus 2009, Cochrane Library (1996 to November 2009), Google and Google Scholar (1996 to November 2009). Thirty-five relevant titles (25 full papers and 10 abstracts) were identified and read by authors. No review has been published in the literature. The publications included describe adverse effects with clomid and selective estrogen receptor modulators and in particular visual disturbances. The population consisted of infertility patients under ovulation induction with CC. The main outcome measures were loss of vision due to CRVO and other visual changes. Results: CC may predispose to CRVO, but further trials are clearly needed in this area. Conclusion: Physicians should be aware of the potential risk of CC, especially in patients with associated risk factors for CRVO. If visual disturbances occur, therapy should be terminated and the patient referred for specialist ophthalmic care.

Journal Section:
Editor's choice
Keywords:
Clomiphene citrate, Retinal vein occlusion, Thrombosis, Visual disturbances, Adverse effects, Visual problems, Selective estrogen receptor modulators
1.
Gewaily D, Greenberg PB: Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2009: CD007324.
2.
Winfried A, Hykin P, Sivaprasad S, The Royal College of Ophthalmologists: Retinal Vein Occlusion Interim Guidelines. 2009, http://www.rcophth.ac.uk.
3.
Madhusudhana KC, Newsom RS: Central retinal vein occlusion: the therapeutic options. Can J Ophthalmol 2007;42:193–195.
[PubMed]
https://doi.org/10.3129%2Fcan+j+ophthalmol.i07-011
4.
Brown J, Farquhar C, Beck J, Boothroyd C, Proctor M, Hughes E: Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation (review). Cochrane Database Syst Rev 2005:CD002249.
5.
Clomid Official FDA Information, Side Effects and Use. www.drugs.com/pro/clomid/html.
6.
Stewart J, Thornton P, Wilson K: Clomid. Food and Drug Administration, 2009.
7.
Hughes E, Collins J, Vandekerckhove P: Clomiphene citrate for ovulation induction in women with oligoamenorrhoea. Cochrane Database Syst Rev 1996:CD000056.
8.
Keskin M, Singur Y, Isler M: Clomiphene-induced acute pancreatitis without hypertriglyceridemia. Am J Med Sci 2007;333:194–196.
[PubMed]
https://doi.org/10.1097%2FMAJ.0b013e3180318da1
9.
Duran JR 3rd, Raja ML: Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report. J Reprod Med 2007;52:1059–1062.
[PubMed]
10.
Yasar HY, Ertugrul O: Clomiphene citrate-induced severe hypertriglyceridemia. Fertil Steril 2009;92:396.e7–e8.
[PubMed]
https://doi.org/10.1016%2Fj.fertnstert.2009.03.069
11.
Benshushan A, Shushan A, Paltiel O, Mordel N, Laufer N: Ovulation induction with clomiphene citrate complicated by deep vein thrombosis. Eur J Obstet Gynecol Reprod Biol 1995;62:261–262.
[PubMed]
https://doi.org/10.1016%2F0301-2115%2895%2902193-B
12.
Chamberlain RA, Cumming DC: Pulmonary embolism during clomiphene therapy for infertility in a male: a case report. Int J Fertil 1986;31:198–199.
[PubMed]
13.
Denniston AKO, Murray PI: Oxford Handbook of Ophthalmology. Oxford, Oxford University Press, 2008.
14.
Tourgeman DE: Alternatives for ovulation induction and superovulation: SERMs and aromatase inhibitors. http://www.infertility.org/alternatives-ovulation-induction.html.
15.
Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E: Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev2009:CD002249.
16.
Boostanfar R, Jain JK, Mishell DR, Paulson RJ: A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001;75:1024–1026.
[PubMed]
https://doi.org/10.1016%2FS0015-0282%2801%2901749-6
17.
Deligisch L: Effects of hormone therapy on the endometrium. Mod Path 1993;6:94–106.
[PubMed]
18.
Rock T, Dinar Y, Romem M: Retinal periphlebitis after hormonal treatment. Ann Ophtalmol 1989;21:75–76.
[PubMed]
19.
Santaella RM, Fraunfelder FW: Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007;67:75–93.
[PubMed]
https://doi.org/10.2165%2F00003495-200767010-00006
20.
Li J, Tripathi RC, Tripathi BJ: Drug-induced ocular disorders. Drug Saf 2008;31:127–141.
[PubMed]
https://doi.org/10.2165%2F00002018-200831020-00003
21.
Rennie IG: Clinically important ocular reactions to systemic drug therapy. Drug Saf 1993;9:196–211.
[PubMed]
https://doi.org/10.2165%2F00002018-199309030-00005
22.
Purvin VA: Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol 1995;113:482–484.
[PubMed]
23.
Lee VY, Liu DT, Li CL, Hoi-Fan, Lam DS: Central retinal vein occlusion associated with clomiphene-induced ovulation. Fertil Steril 2008;90:2011.e11–e12.
[PubMed]
24.
Politou M, Gialeraki A, Merkouri E, Travlou A, Baltatzis S: Central retinal vein occlusion secondary to clomiphene treatment in a male carrier of factor V Leiden. Genet Test Mol Biomarkers 2009;13:155–157.
[PubMed]
https://doi.org/10.1089%2Fgtmb.2008.0104
25.
Viola MI, Matsaseng T, Meyer D, Kruger TF: Association between clomiphene citrate and central retinal vein occlusion. S Afr J Obstet Gynaecol, accepted.
26.
Racette L, Casson PR, Claman P, Zackon D, Casson EJ: An investigation of the visual disturbances experienced by patients on clomiphene citrate. Fertil Steril 2010;93:1169–1172.
[PubMed]
https://doi.org/10.1016%2Fj.fertnstert.2008.11.025
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.